Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:AKUSNASDAQ:FOLDNASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$34.30-0.6%$29.76$23.42▼$62.58$1.99B0.73662,530 shs478,627 shsAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsFOLDAmicus Therapeutics$6.03-2.3%$6.48$5.81▼$12.65$1.86B0.542.98 million shs4.22 million shsIDYAIDEAYA Biosciences$22.18-0.4%$18.94$13.45▼$44.42$1.94B0.041.03 million shs862,850 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-0.09%+21.37%+10.90%-28.50%AKUSAkouos0.00%0.00%0.00%0.00%0.00%FOLDAmicus Therapeutics0.00%-2.11%+1.34%-32.25%-43.33%IDYAIDEAYA Biosciences0.00%+2.07%+28.13%+19.38%-43.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals3.9345 of 5 stars3.41.00.04.21.80.81.9AKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AFOLDAmicus Therapeutics3.9658 of 5 stars3.42.00.04.31.80.01.9IDYAIDEAYA Biosciences3.851 of 5 stars3.52.00.04.42.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6070.85% UpsideAKUSAkouos 0.00N/AN/AN/AFOLDAmicus Therapeutics 2.70Moderate Buy$16.22169.03% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27144.69% UpsideCurrent Analyst Ratings BreakdownLatest AKUS, AGIO, FOLD, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M53.64N/AN/A$27.02 per share1.27AKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AFOLDAmicus Therapeutics$543.14M3.42N/AN/A$0.63 per share9.57IDYAIDEAYA Biosciences$7M277.51N/AN/A$12.10 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.02N/AN/A1,845.92%-2.51%-2.26%7/30/2025 (Estimated)AKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AFOLDAmicus Therapeutics-$151.58M-$0.09N/A14.021.51-10.62%12.44%2.60%8/14/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)Latest AKUS, AGIO, FOLD, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AAKUSAkouosN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56AKUSAkouosN/A17.3017.30FOLDAmicus Therapeutics2.013.392.42IDYAIDEAYA BiosciencesN/A14.9722.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AAKUSAkouosN/AFOLDAmicus TherapeuticsN/AIDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%AKUSAkouos4.80%FOLDAmicus Therapeutics2.20%IDYAIDEAYA Biosciences2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableAKUS, AGIO, FOLD, and IDYA HeadlinesRecent News About These CompaniesCantor Fitzgerald Comments on IDYA FY2026 EarningsJune 12 at 2:49 AM | americanbankingnews.comHere's Why Steve Cohen's Point72 Recently Shelled Out Over $100M for Two Biopharma StocksJune 10, 2025 | msn.comCantor Fitzgerald Forecasts IDYA FY2026 EarningsJune 10, 2025 | marketbeat.comIDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations EventsJune 2, 2025 | prnewswire.comMillennium Management LLC Cuts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)June 1, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Increased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comSquarepoint Ops LLC Buys 33,088 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 27, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Two Sigma Investments LPMay 26, 2025 | marketbeat.comNeo Ivy Capital Management Makes New Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 25, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 24, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock PriceMay 24, 2025 | marketbeat.comTwinbeech Capital LP Sells 71,664 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 24, 2025 | marketbeat.comBank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 22, 2025 | marketbeat.comJane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 22, 2025 | marketbeat.comTema Etfs LLC Purchases New Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 20, 2025 | marketbeat.comPolar Capital Holdings Plc Sells 589,500 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 19, 2025 | marketbeat.comDeutsche Bank AG Grows Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 19, 2025 | marketbeat.comJanuary 2026 Options Now Available For IDEAYA BiosciencesMay 17, 2025 | nasdaq.comMPM Bioimpact LLC Buys Shares of 414,035 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKUS, AGIO, FOLD, and IDYA Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$34.30 -0.20 (-0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.31 +0.01 (+0.03%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Akouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Amicus Therapeutics NASDAQ:FOLD$6.03 -0.14 (-2.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.03 0.00 (0.00%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.IDEAYA Biosciences NASDAQ:IDYA$22.18 -0.10 (-0.45%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.96 -0.22 (-0.99%) As of 06/13/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
